In prostate cancer, metformin was reported to induce the suppression of pro-inflammatory cytokines IL-2, TNF-α, and INF-ɣ, which was correlated with the inhibition of the mTOR Pathway [23]. The gene discussed is IL2; the disease is prostate carcinoma.